Filing Flows › Opus Genetics (IRD) › R&D spending
Opus Genetics (IRD) R&D spending by quarter
Opus Genetics' R&D spending was $11.2M in Q2 2026 (second quarter 2026), +6% from Q1 2026. Over the last 7 quarters it ranged from $6.0M (Q2 2025) to $11.2M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $11.2M | +6% | +86% |
| Q1 2026 | $10.6M | +1% | +33% |
| Q4 2025 | $10.4M | +63% | +48% |
| Q3 2025 | $6.4M | +6% | — |
| Q2 2025 | $6.0M | -24% | — |
| Q1 2025 | $8.0M | +13% | — |
| Q4 2024 | $7.0M | — | — |
Q2 2026 at a glance
Opus Genetics, Q2 2026: revenue $755K (-74% year over year), net loss $8.1M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Opus Genetics' R&D spending?
Opus Genetics' R&D spending was $11.2M in Q2 2026 (second quarter 2026), +6% from Q1 2026.
How has Opus Genetics' R&D spending changed?
Over the last 7 quarters it ranged from $6.0M (Q2 2025) to $11.2M (Q2 2026).